Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool

  • Matilla-Cabello, Gonzalo
  • Remesal-Doblado, Ángela
  • Celebi-Cinar, Muzzez
  • Bodoque-García, Ana
  • Betul Metin, Fatma
  • Rezaei, Aida
  • Aftab, Moiz
  • De los Santos-Fernández, Romina
  • Segovia-Zafra, Antonio
  • Álvarez-Álvarez, Ismael
  • Andrade-Bellido, Raúl Jesús
  • Cakan-Akdogan, Gulcin
  • Lucena-González, María Isabel
  • Konu, Ozlen
  • Villanueva-Paz, Marina
Idiosyncratic drug-induced liver injury (iDILI) is a rare, dose-independent and unpredictable adverse reaction occurring at therapeutic drug exposure, and it presents a significant challenge for drug development and patient safety. Despite extensive research, genetic susceptibility to iDILI remains poorly understood. We conducted a comprehensive systematic study of 139 human genetic studies to identify and characterize genetic polymorphisms associated with increased risk or protection against iDILI. Our study included candidate gene studies and genome-wide association studies (GWAS), encompassing 83 risk and 25 protective genes, with NAT2, HLA-B, and SLCO1B1 among the most frequently reported. We performed functional enrichment analyses using KEGG and Gene Ontology, revealing key biological pathways related to immune response, xenobiotic metabolism, and bile secretion. To enhance data accessibility and interpretation, we developed iDILInet, a publicly available web application that enables interactive exploration and network-based visualization of iDILI-associated gene-variant-drug relationships, enriched with liver-specific expression data from the Human Protein Atlas (HPA). Our work provides a novel integrative resource that supports ongoing efforts in precision medicine and pharmacogenomics and represents a significant advancement in implementing living systematic reviews in toxicogenomics., Consejería de Salud de Andalucía, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Agencia Española del Medicamento y Productos Sanitarios, Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, Universidad de Málaga
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

Epigenetic modifications in drug-induced liver injury: A systematic review

  • de los Santos-Fernández, Romina Lorena
  • Segovia-Zafra, Antonio
  • Paz-López, Guillermo
  • Matilla-Cabello, Gonzalo
  • Niu, Hao
  • Álvarez-Álvarez, Ismael
  • Stephens, Camilla
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • Medina-Cáliz, Inmaculada
Genetic susceptibility has been identified in idiosyncratic drug-induced liver injury, a potentially severe adverse reaction towards drugs, herbal products and dietary supplements. However, its occurrence cannot be fully explained by the presence of genetic variants in specific genes, suggesting that other factors are involved. Druginduced liver injury epigenetic signatures could help explain genetic regulatory mechanisms behind this disease and might provide disease biomarkers. This systematic review aims to analyse all available information on epigenetic risk association studies in drug-induced liver injury. The main inclusion criterion was population studies on idiosyncratic drug-induced liver injury with significant risk association analysis between drug-induced liver injury and an epigenetic regulation mechanism. Out of the 7 included articles, 6 focused on DNA methylation and 1 on long noncoding RNA. All of the studies were on antituberculosis drug-induced liver injury and came from Asia. CpG site methylation in the CYP2D6 (odds ratio: 9.19, 95% confidence interval: 3.26–25.89, P < .001) and NAT2 (odds ratio: 8.37, 95% confidence interval: 2.39–29.32, P = .001) promoters conferred the highest risk. Hypomethylation of LINE-1 and Alu transposable elements has potential as antituberculosis drug-induced liver injury biomarkers, showing an area under the curve value of 0.94. To conclude, the studies mainly focused on DNA methylation modifications associated with antituberculosis drug-induced liver injury, with all of them coming from Asia, where tuberculosis is a public health burden. Despite the lack of knowledge in this area, the evidence has shown that DNA methylation alterations in antituberculosis drug-induced liver injury could have potential as a new diagnostic and therapeutic target., Instituto de Salud Carlos III, Agencia Estatal de Investigación, CIBER, European Comission
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

DILI Differences and Similarities between the US and Europe

  • Toro-Ortiz, Juan Pedro
  • Andrade-Bellido, Raúl Jesús
  • Pinazo-Bandera, José
Purpose of review To evaluate the critical role of international registries in understanding idiosyncratic drug-induced liver injury (DILI) by comparing clinical and epidemiological data from the Spanish DILI Registry, the Pro-Euro DILI registry, and the US DILIN. Recent findings Although amoxicillin-clavulanic acid remains the leading global DILI trigger, DILI cases in the US show higher severity and more herbal supplement involvement. Immune checkpoint inhibitors present new toxicity phenotypes. Registry collaborations have yielded advanced prognostic tools like the nR criteria for predicting liver failure, and RECAM, a novel electronic causality assessment scale offering greater diagnostic precision than RUCAM. Summary Registries are crucial for identifying rare DILI events that are missed by clinical trials, as well as for highlighting regional differences in triggers and outcomes. These networks are essential for identifying diagnostic biomarkers, and their findings benefit not only clinicians, but also regulators. Future research should prioritize the global validation of RECAM and utilize multinational biobanks to identify genetic risk factors, ultimately improving drug safety., Funding for open access charge: Universidad de Málaga / CBUA, Instituto de Salud Carlos III, European Union, Agencia Española de Medicamentos y Productos Sanitarios